Am J Transplant, Volume 3, Suppl 5 Archives - Page 76 of 178 - ATC Abstracts

2013 American Transplant Congress
Pharmacodynamic and Immunomodulatory Effects of TOL-101: An IgM Anti-αβ TCR Monoclonal Antibody Used for Induction Therapy in Kidney Transplantation, The
A. Wiseman, S. Mulgaonkar, L. Melton, T. Waid, A. Agarwal, R. Sung, F. Shihab, D. Getts, S. Flechner
Cleveland Clinic Foundation, Cleveland; Barnabas Health, West Orange; Dallas Transplant Nephrologists, Dallas; University of Virginia, Charlottesville; University of Michigan, Ann Arbor; University of Utah, Salt Lake City; Tolera Therapeutics Inc, Kalamazoo; Northwestern University, Chicago; University of Kentucky, Lexington; University of Colorado, Denver
Purpose: TOL-101 is a novel IgM monoclonal antibody that specifically targets the ΑΒ TCR. Results from a Phase 2 dose finding efficacy study in 28…
2013 American Transplant Congress
Inhibition of Receptor Interacting Protein 3 (RIP3) Promotes Long Term Renal Allograft Survival
A. Lau, S. Wang, A. Haig, Z. Yin, Z. Zhang, A. Jevnikar
Matthew Mailing Centre for Translational Transplant Studies, London, Canada; Western University, London, Canada; Lawson Health Research Institute, London, Canada
Death of kidney parenchymal cells during transplantation occurs through counterbalanced mechanisms of cellular death, apoptosis and necrosis. Members of the receptor interacting protein family (RIP1,…
2013 American Transplant Congress
Dose Escalating Anti-αβ-TCR (TOL101) Monoclonal Therapy, Induces Robust Naive and Memory T Inhibition Whilst Promoting Post Dosing Regulatory T Cell Induction
D. Getts, S. Mulgaonkar, L. Melton, T. Waid, R. Sung, F. Shihab, E. Chastain, R. Terry, S. Miller, A. Wiseman, S. Flechner
Tolera Therapeutics, Kalamazoo; Northwestern University, Chicago; Barnabas Health, West Orange; Dallas Nephrology Associates, Dallas; University of Kentucky, Lexington; University of Michigan, Ann Arbor; University of Utah, Salt Lake City; University of Colorado, Denver; Cleveland Clinic Foundation, Cleveland
Purpose: Induction therapy success hinges on the ability to robustly inhibit alloreactive T cells. The purpose of this study was to further examine the impact…
2013 American Transplant Congress
Trends in Kidney Transplant Outcomes in Older Adults
M. McAdams-DeMarco, N. James, J. Walston, D. Segev
Johns Hopkins University School of Medicine, Baltimore, MD
BACKGROUND: Recent evidence suggests that, in general, kidney transplant (KT) outcomes are improving over time. However, this evidence is population-based, failing to evaluate trends in…
2013 American Transplant Congress
Platelets as Mediator of Alloantibody-Induced Responses in Vascularized Organ Transplantation
H. Kuo, R. Fan, W. Baldwin
Immunology, Lerner Research Institute, Cleveland, OH
Recent research has begun to elucidate the immune function of platelets. A few clinical studies have reported platelet accumulation in renal transplants during acute rejection.…
2013 American Transplant Congress
Differentiation of HCV Activation, Severity, and Acute Rejection Using Expression Profiles of Inflammatory Protein and miRNA in the Serum
A. Shaked, J. Tobias, N. Goodrich, B. Gillespie, the A2ALL Study Group
U of Pennsylvania, Philadelphia, PA; Arbor Research Collaborative for Health, Ann Arbor, MI; U of Michigan, Ann Arbor, MI
The aim of this exploratory study was to determine whether inflammatory proteins and/or miRNA in serum specimens collected near the time of protocol or for…
2013 American Transplant Congress
Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
R. Brown, M. Russo, J. Levitsky, K. Brown, R. Fontana, H. Vargas, E. Yoshida, M. Bsharat, R. Rubin
Columbia University, New York, NY; Carolinas Medical Center, Charlotte, NC; Northwestern University, Chicago, IL; Henry Ford Hospital, Detroit, MI; University of Michigan, Ann Arbor, MI; Mayo Clinic, Scottsdale, AZ; University of British Columbia, Vancouver, BC, Canada; Vertex Pharmaceuticals Incorporated, Cambridge, MA
Background: REFRESH is a 2-part Phase 2b, open-label clinical study assessing safety, efficacy, and pharmacokinetics (PK) of telaprevir (T) in combination with peginterferon alfa-2a (P)…
2013 American Transplant Congress
Antibody-Mediated Rejection (AMR) in Kidney Transplantation: The Role of Anti-Peroxisomal trans-2-enoyl-CoA Reductase (PECR) Auto-Antibody
M. Freitas, L. Rebellato, T. Pham, P. Terasaki
Terasaki Foundation Laboratory, Los Angeles, CA; Department of Pathology, Brody School of Medicine at East Carolina University, Greenville
Introduction: Peroxisomal trans-2-enoyl-CoA reductase (PECR), a cell component of the mitochondria and peroxisomal membrane, is an enzyme involved in the lipid metabolism and fatty acid…
2013 American Transplant Congress
Assessing the Validity of the Kidney Donor Profile Index (KDPI): The MedStar Washington Hospital Center Experience
M. Orquiza, M. Tucker, H. Wang, J. Light
Transplantation Services, MedStar Washington Hospital Center, Washington, DC; MedStar Health Research Institute, Washington, DC
Introduction: Kidney allocation policy is controversial, but it his hoped that the Kidney Donor Profile Index (KDPI) and Estimated Post-Transplant Survival (EPTS) will allow for…
2013 American Transplant Congress
Long-Term Impact of CMV Infection on the Allograft and on Patient Survival in Renal Transplant Patients with Protocol Biopsies
U. Erdbruegger, I. Scheffner, M. Mengel, A. Schwarz, H. Haller, W. Gwinner
Dep. of Medicine, Div. of Nephrology, University of Virginia Health System, Charlottesville; Dep. of Medicine, Div. of Nephrology, Hannover Medical School, Hannover, Germany; Dep. of Laboratory Medicine and Pathology, Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, Canada
We studied 594 patients who had a protocol biopsy (pBx) at 6 weeks, 3 and 6 months post transplant. Chronic allograft changes were evaluated according…